Neurofit Appoints Professor Im Hyun-guk, Dementia Expert and Director of Brain Health Center at Yeouido St. Mary's Hospital, as CMO

Neurofit, a specialized company in AI solutions for brain disease imaging, announced on the 18th that it has recruited Professor Lim Hyun-guk, head of the Catholic Brain Health Center at Yeouido St. Mary's Hospital, as its Chief Medical Officer (CMO) to strengthen research and expand its global business.

CMO Lim Hyun-guk graduated from the Catholic University College of Medicine and earned a Ph.D. in Psychiatry from the same university. He is currently a professor in the Department of Psychiatry at Yeouido St. Mary's Hospital, Catholic University. He is recognized as one of the leading authorities in dementia diagnosis and treatment in Korea and serves as the Publication Director of the Korean Neuropsychiatric Association, Academic Director of the Korean Geriatric Psychiatry Association, General Director of the Korean Biological Psychiatry Association, Academic Director of the Cognitive Intervention Therapy Association, and Expert Committee Member of the Central Dementia Center at the National Medical Center. Notably, the Catholic Brain Health Center at Yeouido St. Mary's Hospital is the only Korean research institution affiliated with the Global Davos Alzheimer's Collaborative, a global multilateral association promoting joint responses to Alzheimer's disease, participating in global collaborative research on Alzheimer's disease.

Since 2018, CMO Lim Hyun-guk has collaborated with Neurofit on initial research for Neurofit's core technology, brain neurodegeneration imaging analysis software. He is also a key researcher in the 'ATNV Project,' a government-funded dementia research and development support project, conducting joint research. This project aims to advance dementia imaging diagnostic technology to utilize Neurofit's imaging diagnostic technology from dementia diagnosis to therapeutic intervention, prognosis confirmation, and research on the efficacy of new dementia drugs.

CMO Lim Hyun-guk stated, “I plan to directly lead dementia-related clinical research at Neurofit and spearhead the core ATNV project. With the Alzheimer's disease treatment 'Lecanemab,' which has received accelerated approval from the U.S. Food and Drug Administration (FDA), expected to be launched in domestic and international markets next year, we aim to create opportunities for Neurofit's products to be indispensably used in Alzheimer's treatment clinical trials and prescriptions.”

The Alzheimer's disease treatment Lecanemab is a new drug that removes beta-amyloid proteins accumulated in the brain. However, it has the common side effect of 'ARIA (Amyloid-Related Imaging Abnormalities),' which occurs with anti-amyloid antibody treatments.

When prescribing anti-amyloid antibody treatments for Alzheimer's patients, it is necessary to confirm the reduction in beta-amyloid accumulation after prescription compared to the amount before prescription through PET (Positron Emission Tomography) imaging. Monitoring and managing ARIA side effects are also essential. Neurofit expects its ATNV technology, capable of quantitative PET imaging analysis and ARIA analysis, to play a key role in future therapeutic clinical trials and prescription fields.

Bin Jun-gil, CEO of Neurofit, said, “By recruiting dementia expert CMO Lim Hyun-guk, we can accelerate the advancement of ATNV research and product development. CMO Lim has direct networks with global pharmaceutical companies developing Alzheimer's treatments, so we expect to achieve tangible results in business aspects in the future.”

This content was produced with the assistance of AI translation services.